Abstract 1780P
Background
In the backdrop of keener scrutiny of health equity issues, the impact of a new intervention on inequality in health outcomes is increasingly viewed as an element in health technology assessment. Non-Hispanic (NH) Black patients are disproportionally affected by non-metastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is an approved treatment for nmCRPC and was shown to be effective and safe among NH-Black patients in the ARAMIS trial. The objective of this study was to quantify the health inequality impact of darolutamide+ androgen-deprivation therapy (ADT) relative to ADT for nmCRPC in the U.S. by means of a distributional cost-effectiveness analysis.
Methods
With a decision model, the quality-adjusted life years (QALYs) and costs were estimated for NH-White, NH-Black, Asian, and Hispanic patients. The degree of differences in QALYs among these subgroups was expressed with Atkinson relative inequality indices (0 = equal outcomes and 1 = maximum inequality between subgroups) for both strategies. Their difference was defined as the inequality impact of darolutamide among treated patients. Subtracting equally distributed health opportunity costs from the QALY gains with darolutamide facilitated calculation of the overall health inequality impact across population subgroups.
Results
Darolutamide+ADT resulted in an additional 1.04 (95% confidence interval 0.57; 1.49) QALYs per treated patient relative to ADT, with the greatest gain observed among NH-Black patients (1.48 QALYs (0.49; 2.72)). The relative inequality in QALYs among patients reduced by 66%, from an inequality score of 0.032 (0.004; 0.080) with ADT to 0.011 (0.000; 0.049) with darolutamide+ADT. Factoring in health opportunity costs, treatment of eligible nmCRPC patients with darolutamide resulted in the largest net gain in QALYs among the NH-Black population, thereby having a favorable impact on inequalities in quality adjusted life expectancy.
Conclusions
Darolutamide+ADT for the treatment of nmCRPC results in greater health outcomes than ADT, and reduces inequality in health outcomes across subgroups according to race and ethnicity in the U.S.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bayer Pharmaceuticals.
Disclosure
J. Janssen, T. Flottemesch, I. Brewer, P. Sullivan: Financial Interests, Institutional, Full or part-time Employment, Precision heor was hired by Bayer to perform the research: PRECISIONheor. J. Partridge: Financial Interests, Personal, Full or part-time Employment, Full time employee of Bayer: Bayer Pharmaceuticals.
Resources from the same session
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14
1774P - PC-PEP, a comprehensive daily six-month home-based prostate cancer: Patient empowerment program improves quality of life, physical fitness, and urinary function outcomes among prostate cancer patients with localized disease - Secondary analyses of a randomized clinical trial
Presenter: Gabriela Ilie
Session: Poster session 14
1775P - A newly-developed deep-learning algorithm: NAFNet outperforms ResNet50 for predicting adverse pathology events and biochemical recurrence time using MRI from prostate cancer patients
Presenter: Zheng Liu
Session: Poster session 14
1776P - Body composition in adult life and prostate cancer (PCa) incidence and mortality: The PROCA-life study
Presenter: Martin Støyten
Session: Poster session 14
1777P - Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
Presenter: Ugo De Giorgi
Session: Poster session 14
1778P - Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Presenter: Stephen Freedland
Session: Poster session 14
1779P - PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial
Presenter: Giulio Francolini
Session: Poster session 14
1782P - Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison
Presenter: Craig Jones
Session: Poster session 14
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14